Aberrant Hypermethylation-Mediated Suppression of PYCARD Is Extremely Frequent in Prostate Cancer with Gleason Score ≥ 7

Figure 2

MSP and immunohistochemical analyses of PYCARD in prostate cancer specimens. (a) MSP analyses of PYCARD in 50 pairs of primary prostate tumors (T) and normal prostate epithelia (N). M and U indicate methylated- and unmethylated-specific PCR products, respectively. Red numbers indicate patients with tumor specific methylation. (b) Representative results of immunohistochemistry with HE staining in case no. 24. (c) Summary of immunohistochemical analyses. Results of individual patients are shown in Table S2.

(a)

(b)

(c)